# A Study to Evaluate the Efficacy and Safety of IBI302 inSubjects With Diabetic Macular Edema（DME）

> **NCT06908876** · PHASE2 · RECRUITING · sponsor: **Innovent Biologics Technology Limited (Shanghai R&D Center)** · enrollment: 150 (estimated)

## Conditions studied

- Diabetic Macular Oedema

## Interventions

- **BIOLOGICAL:** IBI302
- **BIOLOGICAL:** IBI302
- **DRUG:** Faricimab

## Key facts

- **NCT ID:** NCT06908876
- **Lead sponsor:** Innovent Biologics Technology Limited (Shanghai R&D Center)
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-04-24
- **Primary completion:** 2026-12-31
- **Final completion:** 2027-02-28
- **Target enrollment:** 150 (ESTIMATED)
- **Last updated:** 2025-05-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06908876

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06908876, "A Study to Evaluate the Efficacy and Safety of IBI302 inSubjects With Diabetic Macular Edema（DME）". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT06908876. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*